NVS vs TMDX
Novartis AG vs TransMedics Group, Inc. — AI-powered side-by-side comparison
VS
TMDX
TransMedics Group, Inc.
60
Buy
| Metric | NVS | TMDX |
|---|
| AI Score |
75
|
60
|
| Price |
$154.64
|
$89.39
|
| P/E Ratio |
23.55×
|
20.22×
|
| ROE |
30.5%
|
40.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
58.7%
|
| Debt / Equity |
1.18×
|
1.68×
|
| Dividend Yield |
2.9%
|
0.0%
|
| RSI (14) |
57.7
|
76.9
|
| Beta |
0.462
|
1.88
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus TMDX.
NVS leads by 15 points.
NVS scores 75/100 (Buy) versus TMDX at 60/100 (Buy).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TMDX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 25.8% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 26.6% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 33.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 25.8% YoY -- genuine top-line momentum — Growth
- EPS growing 105.5% YoY — Growth
Bear Case
- Price-to-book of 8.8x prices in significant intangible value — Value
- RSI at 77 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical